TetraDerm Cohort 1 Results

Tetratherix Limited (ASX: TTX) reports performance of TetraDerm in Scar prevention, reaching major clinical milestone

The surgical community has spent decades managing the failure of human tissue to heal without visible scar trauma. At Tetratherix, we are not interested in accepting this failure; we are focused on engineering its absence.

Our interim results for TetraDerm represent a fundamental disruption of the scar-formation narrative. By intervening in the "dead space" of a wound with a liquid-to-gel phase transition that mimics biological scaffolding, we have achieved a Vancouver Scar Scale (VSS) score of 1.1 out of 13 at twelve months. To be clear: 0 is healthy skin.

The Architecture of Prevention

• Biological Integration: TetraDerm transforms from a liquid to a cohesive, adhesive gel using the patient’s own body heat to support natural healing.

• Quantifiable Success: Interim Cohort 1 data shows negligible scar formation, with results improving from 13% at 3 months to just 8% at 12 months.

• Operational Velocity: We have already pivoted into our final clinical cohort for complex reconstructive surgeries.

The Global Opportunity

We are systematically de-risking our entry into the $US 2.1 billion wound closure market. With 12 million procedures globally—from C-sections to joint replacements—the demand for a seamless, cost-effective prevention tool is not just a commercial opportunity; it is a clinical necessity.

We are building the infrastructure for a new global standard where the "inevitability" of scarring is rendered obsolete.

The future of tissue healing isn't a treatment. It's a technology.

Hear from Dr Ali Fathi, our Chief Technology Officer, about this major clinical milestone for TetraDerm.

Read the full ASX Announcement on our Investor Hub: https://investors.tetratherix.com/link/P3DM0y